NEW YORK – Hutchmed on Wednesday said it started a Phase I/IIa trial of its antibody-targeted therapy conjugate (ATTC) HMPL-A580 in patients with unresectable, advanced or metastatic solid tumors.
Geographic expansion driving ex-China sales growth; indication expansions driving China sales growth —— $457 million net income, driven by ...
Geographic expansion driving ex-China sales growth; indication expansions driving China sales growth - - $457 million net income, driven by profitable core operations and non-core disposal - - Rapidly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results